Search results
Agenus' Investigational Cancer Combo Therapy Shows 33% Durable Responses In Ovarian Cancer
Benzinga via Yahoo Finance· 1 year agoAgenus Inc (NASDAQ: AGEN) announced results from a cohort of 24 evaluable patients in an expansion...
Agenus Presents Clinical Data Demonstrating Durable Responses For Colorectal Cancer Candidate
Benzinga via Yahoo Finance· 1 year agoAgenus Inc (NASDAQ: AGEN) announced clinical data from the MSS CRC (microsatellite stable colorectal...
Seres Therapeutics Inc (MCRB) Announces Q3 2023 Financial Results and Strategic Restructuring
GuruFocus.com via Yahoo Finance· 8 months agoSeres Therapeutics Inc (NASDAQ:MCRB) reported Q3 2023 financial results, including VOWST net sales...
Why Immatics Stock Is Soaring Today
Motley Fool· 1 year agoWhat happened Shares of Immatics NV (NASDAQ: IMTX) were soaring 17.5% as of 11:03 a.m. ET on Tuesday and jumped as much as 36.3% earlier in the day. The...
Agenus Touts 'Unprecedented Activity' For Botensilimab/Balstilimab Combo In Colorectal Cancer
Benzinga via Yahoo Finance· 2 years agoAgenus Inc (NASDAQ: AGEN) has announced expanded data from the Phase 1b study of botensilimab and...
Third Harmonic Bio Stock Plummets After Trial Discontinuation On Safety Concerns
Benzinga via Yahoo Finance· 2 years agoThird Harmonic Bio Inc (NASDAQ: THRD) will discontinue the ongoing Phase 1b study of THB001 in...
Altimmune Shares Fall Despite Fatty Liver Disease Study Meets Primary Goal
Benzinga via Yahoo Finance· 2 years agoAltimmune Inc (NASDAQ: ALT) shares plunged after topline results from its 12-week Phase 1b study of...
Assembly Biosciences Shares Gain After Promising Early Cut Data From HBV Infection Programs
Benzinga via Yahoo Finance· 1 year agoAssembly Biosciences Inc (NASDAQ: ASMB) announced interim efficacy, safety, and pharmacokinetic (PK)...
Rallybio Pulls Plug On One Candidate After Highlighting Encouraging Data From Another...
Benzinga via Yahoo Finance· 1 year agoRallybio Corporation (NASDAQ: RLYB) says clinical proof-of-concept has been achieved in Phase 1b...
Read How Cantor Views Celldex Therapeutics' Barzolvolimab Data
Benzinga via Yahoo Finance· 2 years agoCelldex Therapeutics Inc's (NASDAQ: CLDX) shares closed almost 16% down on Friday after releasing...
